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Abstract: Recent advances in the detection of germline pathogenic variants (PVs) in BRCA1/2 genes
have allowed a deeper understanding of the BRCA-related cancer risk. Several studies showed
a significant heterogeneity in the prevalence of PVs across different populations. Because little is
known about this in the Sicilian population, our study was aimed at investigating the prevalence
and geographic distribution of inherited BRCA1/2 PVs in families from this specific geographical
area of Southern Italy. We retrospectively collected and analyzed all clinical information of 1346
hereditary breast and/or ovarian cancer patients genetically tested for germline BRCA1/2 PVs at
University Hospital Policlinico “P. Giaccone” of Palermo from January 1999 to October 2019. Thirty
PVs were more frequently observed in the Sicilian population but only some of these showed a specific
territorial prevalence, unlike other Italian and European regions. This difference could be attributed
to the genetic heterogeneity of the Sicilian people and its historical background. Therefore hereditary
breast and ovarian cancers could be predominantly due to BRCA1/2 PVs different from those usually
detected in other geographical areas of Italy and Europe. Our investigation led us to hypothesize
that a higher prevalence of some germline BRCA PVs in Sicily could be a population-specific genetic
feature of BRCA-positive carriers.
Keywords: BRCA1; BRCA2; breast cancer; founder variants; genetic testing; germline pathogenic
variants; hereditary breast and ovarian cancer; ovarian cancer; Sicilian population
1. Introduction
Inherited pathogenic variants (PVs) in BRCA1 or BRCA2 genes cause a significantly increased
risk for breast cancer (BC) [1], ovarian cancer (OC) [2] and other tumors including pancreas [3,4] and
prostate cancer [5–7].
Although BC and OC are more frequently sporadic tumors (75–80%), approximately 15–20% is
familial type and about 5–10% of cases is hereditary. BRCA1 and BRCA2 are the most known genes
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associated with hereditary breast and/or ovarian cancer (HBOC) risk [8]. However, the hereditary
forms could be associated with germline PVs in several genes which confer a different risk to develop
a neoplasm. PVs in genes such as ATM, CHEK2, BARD1, BRIP1, RAD51C, RAD51D, confer a moderate
risk and, for this reason, the clinical management of PV carriers is, to date, still debated and requires
further in-depth clinical studies [9–11]. PVs in BRCA1/2, CDH1, PALB2, PTEN, STK11 and TP53 genes
confer a high risk to develop BC [12] but also OC or other tumors [13–17]. Specifically, BRCA1 PV
carriers show a 50–85% risk of developing BC during their lifetime, 40–60% risk of developing bilateral
BC and 15–45% risk of develop OC or tubal carcinoma. Germline BRCA2 PV carriers, like BRCA1 PV
carriers, exhibit a 50–85% risk of BC but a lower risk (10–20%) of developing OC [18,19].
BRCA1-associate BCs show frequently a poorly differentiated infiltrating ductal histotype,
high proliferative activity (ki-67), negativity of hormone receptors for estrogens (ERs) and progesterone
(PR) and absence of HER2/neu amplification (“triple-negative” phenotype, TNBC) [20]. These tumors
are associated with higher mortality and morbidity and therefore involve only the use of conventional
chemotherapy as therapeutic option. Instead, BRCA2-associated BCs have a molecular profiling that
resembles the luminal A or B tumor subtypes [21,22] as well as a slight increase in the incidence of the
lobular histotype compared to sporadic forms [23,24].
In the OC, the prevalence of BRCA1/2 PVs is high (17–20%), especially in patients with serous
tumors [25] and increases up to 23–25% in the high-grade serous histotype [26], independently of age
of diagnosis and family history. For this reason, in the OC patients, according to the current guidelines,
the BRCA testing is performed in all non-mucinous and non-borderline ovarian epithelial carcinoma,
fallopian tube carcinoma and primary peritoneal carcinoma. The individuals and family members
eventually BRCA PV carriers will be directed towards dedicated high-risk follow-up programs and
specific risk-reducing strategies. Furthermore, today, genetic testing result has substantial clinical
implications for patient care. In addition to preventive pathways for early diagnosis and cancer
risk reduction developed for individuals at high-risk and their relatives, BRCA testing has become a
predictive biomarker of therapy response [27].
Recently, several studies have demonstrated that the prevalence of germline PVs and gene-specific
risk estimates could change, not only based on family history and type/molecular subtype of the
tumors but also on the basis of race, ethnicity and different geographic location [28–30].
Although today population-based testing for hereditary BC and OC risk is not yet widespread,
some studies evaluating population-based PVs mostly in the Jewish population are beginning to
provide new information and new knowledge and, in the future, could lead to new directions in
genetic testing in select groups of subjects [29,31,32]. Currently, the most used population model for
studying the feasibility and efficacy of the population-based BRCA testing is represented by Jewish
population; however, implementation studies are needed for testing multiple cancer susceptibility
genes in the general population [29]. Therefore, the current guidelines for genetic testing, based on
clinical criteria and family history, could be replaced by new approaches able to detect the 50% more
BRCA carriers than those identified by conventional criteria [33,34].
In this context, little is known about the prevalence and geographic distribution of inherited PVs
in BRCA1/2 genes in the Sicilian population. For this purpose, in this work we performed a genetic
screening for germline BRCA1 and BRCA2 PVs in Sicilian breast and/or ovarian cancer patients and
their relatives, in order to assess the prevalence and typology of these high-risk susceptibility variants
in individuals belonging to this specific geographical area of Southern Italy.
2. Results
2.1. Clinical Features of Breast and/or Ovarian Cancer Patients Harbouring Germline BRCA1/2
Pathogenic Variants
One thousand three hundred and forty six breast and/or ovarian cancer patients who met the
previously established inclusion criteria (see Patients and Methods section) were recruited and studied
over a period ranging from January 1999 to October 2019 at the “Regional Center for the prevention,
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diagnosis and treatment of rare and heredo-familial tumors of adults” of the Section of Medical
Oncology of the University Hospital Policlinico “P. Giaccone” of Palermo. A substantial increase in the
request and indication of BRCA testing for cancer risk assessment, resulting in gradual increase also in
the number of PV carriers, was observed at our Centre during these years (Figure S1). In particular,
a sharp increase in BRCA testing number was observed from 2016 to 2017, when BRCA testing has
acquired a predictive value of response to the therapy by PARP inhibitors. This Guidelines change
has allowed to extend the BRCA testing for therapeutic purposes to all patients with non-mucinous
and non-borderline ovarian epithelial carcinoma, fallopian tube carcinoma and primary peritoneal
carcinoma, also in absence of cancer family history.
All 1346 probands, after appropriate genetic counselling, were genetically tested for germline PVs
in BRCA1 and BRCA2 genes. 200 (14.8%) out of 1346 probands with breast and/or ovarian cancer have
been shown to harbour germline BRCA1/2 PVs. Our investigation showed that 102 (51%) out of 200
BRCA variant-positive individuals were BRCA1 PV carriers, 96 subjects (48%) were BRCA2 PV carriers
and 2 patients (1%) showed a double heterozygosity for BRCA1 and BRCA2 PVs. Among 102 BRCA1 PV
carriers, 59 individuals (57.8%) had female breast cancer, 8 of which bilateral (13.5%), 19 triple-negative
breast cancer (TNBC) (32.2%) and 9 diagnosed before age 35 years (15.2%), 29 patients (28.4%) had
ovarian cancer, 27 of which high-grade serous (93.1%) and 2 endometrioid (6.9%), 11 subjects (10.8%)
had both primary ovarian and breast cancer, 3 patients (2.9%) had male breast cancer (Figure 1a;
Table 1).
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Figure 1. Breast and/or ovarian cancer patients harboring germline BRCA1/2 pathogenic variants (PVs).
200 (14.8%) out of 1346 probands with breast and/or ovarian cancer had germline PVs in BRCA1/2
genes. (a) 102 (51%) were BRCA1 PV carriers, (b) 96 (48%) were BRCA2 PV carriers and 2 patients (1%)
showed a double heterozygosity for BRCA1 and BRCA2 PVs.
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Table 1. Number of patients with Hereditary Breast/Ovarian Cancer (HBOC) and BRCA1/2 pathogenic variants (PVs) (1999–2019), type of tumors (breast cancer,
ovarian cancer, breast and ovarian cancers, male breast cancer), median age at diagnosis and family history.
BRCA1/2 PVs
Positive/Total HBOC
n = 200/1346 (14.8%)
BRCA1 PVs Positive
n = 102 (51%)
BRCA2 PVs Positive
n = 96 (48%)
DH BRCA1-
BRCA2 PVs
n = 2 (1%)
Type of cancer
Breast
cancer
n = 59
(57.8%)
Ovarian
cancer
n = 29
(28.4%)
Breast and
ovarian cancers
n = 11
(10.8%)
Male breast
cancer
n = 3
(2.9%)
Breast
cancer
n = 69
(71.9%)
Ovarian
cancer
n = 16
(16.7%)
Breast and
ovarian cancers
n = 6
(6.2%)
Male breast
cancer
n = 5
(5.2%)
Bilateral
Breast cancer
n = 2
(100%)
Age at diagnosis (yr),
median (range)
41
(28–62)
52
(39–69)
BC 48
(36–77) 60
(67–73)
41
(25–80)
59
(40–81)
BC 50
(39–78) 67
(62–68)
Patient 1
37,41
OC 53
(39–78)
OC 57
(41–79)
Patient 2
54,54
Family history
Yes, n = 53 (26.5%)
No, n = 147 (73.5%)
20 (33.8%)
39 (66.2%)
7 (24.1%)
22 (75.9%)
2 (18%)
9 (82%)
0 (0%)
3 (100%)
16 (23.2%)
53 (76.8%)
4 (25%)
12 (75%)
2 (33.3%)
4 (66.7%)
0 (0%)
5 (100%)
2 (100%)
0 (0%)
Abbreviations: BC = Breast Cancer; OC = Ovarian Cancer; PVs = Pathogenic Variants; HBOC= Hereditary Breast/Ovarian Cancer; DH = Double Heterozygosity.
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Among 96 BRCA2 PV carriers, 69 individuals (71.9%) had female breast cancer, 14 of which
bilateral (20.3%), 9 TNBC (13%) and 20 diagnosed before age 35 years (29%), 16 patients (16.7%) had
ovarian cancer, 15 of which high-grade serous (93.7%) and 1 endometrioid (6.3%), 6 subjects (6.2%) had
both primary ovarian and breast cancer, 5 patients (5.2%) had male breast cancer (Figure 1b; Table 1).
Finally, two patients showing a double heterozygosity for BRCA1 and BRCA2 PVs were probands
with BC, one of which TNBC and the other bilateral (luminal B subtype).
In our study, TNBCs account for 25% of all BRCA-variant breast cancers present in probands: 70%
of these was related to BRCA1 PVs and 30% was associated to BRCA2 PVs. Also, it has been observed
that 37% of genetically tested TNBC patients was carrier of germline PVs in BRCA genes.
2.2. Clinical Features of Germline BRCA1/2 PV Carriers
Afterwards, in our study we have also included the relatives of BRCA-positive probands enrolled
at our Centre in the same period of time ranging from January 1999 to October 2019. Six hundred and
twenty one family members were enrolled and tested for mutational analysis in BRCA1/2 genes and 285
(45.9%) out of the 621 family members have been shown to be carriers of a BRCA1/2 PV. Considering
both probands and family members, overall 1967 individuals were genetically tested for BRCA1/2 PVs
at our Centre. Our analysis showed that 485 (24.6%) out of 1967 enrolled subjects (probands and family
members) harbor a germline BRCA1/2 PV (Figure S2).
Out of 485 individuals, 259 (53.4%) were BRCA1 PV carriers, 222 subjects (45.8%) were BRCA2
PV carriers and 4 individuals (0.8%) showed a double heterozygosity for BRCA1 and BRCA2 PVs.
Among 259 BRCA1 PV carriers, 116 individuals (44.8%) were patients with cancer diagnosis related to
hereditary breast and/or ovarian cancer syndrome, 133 subjects (51.3%) were healthy and 10 individuals
(3.9%) were excluded from the study for lack of sufficient information. Of 116 cancer patients, 71 (61.2%)
had female breast cancer, 11 of which bilateral (15.5%) and 8 diagnosed before age 35 years (11.3%),
30 patients (25.9%) had ovarian cancer, 12 patients (10.3%) had both primary ovarian and breast cancer
and 3 patients (2.6%) had male breast cancer (Figure 2a, Table 2).
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Figure 2. Type of tumors in all individuals carrier of germline BRCA1 (a) or BRCA2 (b) PVs (probands
and family members).
Among 222 BRCA2 PV carriers, 105 individuals (47.3%) were cancer patients, 109 subjects (49.1%)
were healthy and 8 individuals (3.6%) were excluded from the study for lack of sufficient information.
78 (74.2%) out of 105 cancer patients had female breast cancer, 15 of which bilateral (19.2%) and 20
diagnosed below age 35 years (25.6%), 17 patients (16.2%) had ovarian cancer, 5 patients (4.8%) had
both primary ovarian and breast cancer and 5 patients (4.8%) had male breast cancer (Figure 2b,
Table 2).
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Table 2. Total number of tested individuals (probands and family members), number of individuals carrier of germline BRCA1/2 PVs and type of tumors.
BRCA1/2 PVs Positive
n = 485/1967 (24.6%).
BRCA1 PVs Positive
n = 259/485 (53.4%)
BRCA2 PVs Positive
n = 222/485 (45.8%)
DH BRCA1-2 PVs
n = 4/485 (0.8%)
No evidence of cancer n.244 133 (51.3%) 109 (49.1%) 2 (50%)
Lack of information n.18 10 (3.9%) 8 (3.6%) –
Diagnosis of cancer n.223 116 (44.8%) 105 (47.3%) 2 (50%)
Type of cancer BC 71(61.2%)
OC 30
(25.9%)
BC and OC
12(10.3%)
MBC 3
(2.6%)
BC 78
(74.2%)
OC 17
(16.2%)
BC and OC
5(4.8%)
MBC 5
(4.8%) BC 2 (100%)
Abbreviations: BC = Breast Cancer; OC = Ovarian Cancer; MBC = Male Breast Cancer; PVs = Pathogenic Variants; DH = Double Heterozygosity.
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Finally, 2 out of 4 subjects showing a double heterozygosity for BRCA1 and BRCA2 PVs were
probands with BC and the other two were healthy family members.
2.3. Typology and Distribution of BRCA1/2 PVs in the Sicilian Population
Our investigation mainly aimed to assess the typology and prevalence of germline BRCA1 and
BRCA2 PVs in individuals belonging to different geographical areas of Sicilia. Mutational analysis
revealed that 99 BRCA1/2 variants (classes III and V), 58 of which in BRCA2 and 41 in BRCA1,
were present in the 1346 genetically tested probands. No large rearrangements were detected in
the 1346 probands through CNV analysis. Based on the classification criteria developed by the
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) consortium
(https://enigmaconsortium.org/) and according to IARC recommendations [35], 64 out of 99 BRCA1/2
variants were classified as pathogenic (class V) and 35 were variants of uncertain significance (VUS;
class III) (Tables S1 and S2). Among the 202 PVs identified in the patient cohort, that also included 4
PVs harbored by two probands with double heterozygosity for BRCA1 and BRCA2, 64 were different
PVs. Thirty most recurrent germline PVs were observed in the Sicilian population. The most frequent
germline BRCA PVs present in the Sicilian population are reported in Tables 3 and 4.
The most frequent PV identified in most BRCA-positive carriers is named BRCA1-5083del19
(HGVS nomenclature: c.4964_4982del; p.Ser1655fs). The analysis of the haplotype of carriers of this PV
showed that these subjects originate from a common ancestor [36–39]. This variant was observed in
several families with breast and ovarian cancer and was first described as a Calabrian/Southern Italian
founder variant [40] but today it is considered a potential Sicilian founder mutation [41]. Thirteen
percent of all BRCA-positive carriers was carrier of this germline PV, which was detected in 18 Sicilian
families, involving a total of 63 carriers (18 probands, 45 family members), of which 25 cancer patients
(39.68%). Among cancer patients harboring this founder variant, 12 individuals had breast cancer,
12 ovarian cancer and one patient only had both primary ovarian and breast cancer. This founder
variant was mainly observed in several families from the Western Sicily, especially in the geographical
areas including the cities of Palermo (located on the northern coast of Sicily) and Agrigento (located on
the southern coast of Sicily) and respective neighboring areas.
Another less recurrent Sicilian PV with potential “founder effect” is named BRCA1-4843delC
(HGVS nomenclature: c.4583del; p.Pro1528fs) [42] and was detected in 7 individuals only (2 of which
were BC patients) from the city of Palermo.
The second most frequent PV, found in 12 families and involving a total of 49 subjects (10.1%),
including 20 cancer patients (12 probands and 8 family members), is named BRCA2-1466delT (HGVS
nomenclature: c.1238del; p.Leu413fs) [43–46]. Most of the Sicilian cancer patients harboring this PV
had breast cancer (19 subjects) and one only ovarian cancer. This sequence variant was specifically
observed in several families from North-Western Sicily, particularly in the geographical area including
the city of Palermo and neighboring areas (for example, the small town of Montemaggiore Belsito).
The third most frequent PV, observed in 14 families and involving a total of 38 subjects (8%),
including 15 cancer patients (14 probands and 1 family member), is named BRCA1-633delC (HGVS
nomenclature: c.514del; p.Gln172fs) [39,47]. Among Sicilian cancer patients harboring this PV,
8 individuals had breast cancer, 6 ovarian cancer and one patient only had both primary ovarian and
breast cancer. This PV was mainly observed in some subjects from the Northern Sicily, especially in the
geographical areas including the cities of Palermo (western coast of Sicily) and Messina (eastern coast
of Sicily) and respective neighboring areas.
A PV, mainly observed in some families from North-Western Sicily (16 individuals, 5 of which
cancer patients) belonging to the geographical area that includes the city of Trapani and neighboring
areas, is named BRCA2-6310del5 (HGVS nomenclature: c.6082_6086del; p.Glu2028fs) [48,49]. Among
cancer patients harboring this PV, 3 subjects had breast cancer, 1 ovarian cancer and 1 both primary
ovarian and breast cancer.
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Table 3. Type and frequency of germline BRCA1 PVs (class V) and geographical area of origin of BRCA carriers.
BIC
NOMENCLATURE HGVS NOMENCLATURE
TYPE OF
BRCA1
PV
BRCA1 PV
CARRIERS
(Patients and
Family Members)
BRCA1 PV
Cancer
Patients
ALLELE
FREQUENCY
(ExAC */
GnomAD **)
ALLELE
FREQUENCY
(Sicilian
Population)
GEOGRAPHICAL
AREA
5083del19 (S551fs) c.4964_4982del (p.Ser1655fs) Deletion 63 (13.0%) 25 (39.68%) ExAC0.000008 0.00928 Palermo and Agrigento
633delC (Q172fs) c.514del (p.Gln172fs) Deletion 38 (7.83%) 15 (39.47%)
ExAC
0.000008
GnomAD
0.000004
0.00557 Palermo and Messina
1479delAG c.1356_1357AG [2](p.Glu453_Ser454insTer) Deletion 14 (2.87%) 6 (42.86%)
ExAC
0.000016
GnomAD
0.000008
0.00222 Deletion
4446C > T (R1443X) c.4327C > T (p.Arg1443Ter) SNV 12 (2.48%) 6 (50.0%) - 0.00222 Palermo and Trapani
2841G > T (E908X) c.2722G > T (p.Glu908Ter) SNV 11 (2.28%) 4 (36.36%) - 0.00148 Palermo, Agrigento,Caltanissetta and Enna
5382insC c.5266dupC (p.Gln1756Profs) Duplication 11 (2.28%) 6 (54.54%)
ExAC
0.000156
GnomAD
0.00018
0.00222 Messina
5149del4 (T1677fs) c.5030_5033del (p.Thr1677fs) Deletion 11 (2.28%) 2 (18.18%) - 0.00074 Caltanissetta andPalermo
3347delAG c.3226_3227AG [1] (p.Gly1077fs) Deletion 10 (2.07%) 4 (40.0%) GnomAD0.000004 0.00148 Palermo
916delTT (S220fs) c.798_799del (p.Ser267fs) Deletion 10 (2.07%) 5 (50.0%) - 0.00185 Palermo
4023G > T (E1302X) c.3904G > T (p.Glu1302Ter) SNV 8 (1.66%) 6 (75.0%) - 0.00222 Caltanissetta
184T > C (L22S) c.65T > C (p.Leu22Ser) SNV 8 (1.66%) 2 (25.0%) - 0.00074 Palermo
300T > G (C61G)*** c.181T > G (p.Cys61Gly)*** SNV 8 (1.66%) 2 (25.0%)
ExAC
0.000067
GnomAD
0.000032
0.00074 Ragusa and Palermo
4843delC (P1596fs) c.4583del (p.Pro1528fs) Deletion 7 (1.45%) 2 (28.57%) - 0.00074 Palermo
3519G > T (E1134X) c.3400G > T (p.Glu1134Ter) SNV 5 (1.03%) 2 (40.0%) GnomAD0.000004 0.00074 Palermo
3372insA c.3253dupA (p.Arg1085Lysfs) Duplication 5 (1.03%) 1 (20.0%) - 0.00037 Catania
* Dataset ExAC v1.0; ** Dataset GnomAD v2.1.1. *** This PV is present together with the PV IVS18 + 2T > C (HGVS: c.8331 + 2T > C) (reported in Table S2) in one of two probands showing
double heterozygosity for BRCA1 and BRCA2, therefore the total number of BRCA1 PV cancer patients is 104 and the total number of BRCA2 cancer patients is 98.
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Table 4. Type and Frequency of Germline BRCA2 PVs (class V) and Geographical Area of Origin of BRCA Carriers.
BIC
NOMENCLATURE HGVS NOMENCLATURE
TYPE OF
BRCA2
PV
BRCA2 PV
CARRIERS
(Patients and
Family Members)
BRCA2 PV
Cancer
Patients
Allele
Frequency
(ExAC */
GnomAD **)
Allele
Frequency
(Sicilian
Population)
GEOGRAPHICAL
AREA
1466delT (L413fs) c.1238del (p.Leu413fs) Deletion 49 (10.10%) 20 (40.82%) GnomAD0.000004 0.00742 Palermo
6079del4 (S1951fs) c.5851_5854del (p.Ser1951fs) Deletion 17 (3.50%) 8 (47.06%) - 0.00297 Trapani and Palermo
6310del5 (E2028fs) c.6082_6086del (p.Glu2028fs) Deletion 16 (3.30%) 5 (31.25%)
ExAC
0.000008
GnomAD
0.000004
0.00185 Trapani
IVS19 + 1G > A c.8487 + 1G > A SNV 10 (2.07%) 4 (40.0%) - 0.00148 Messina, Palermo andCaltanissetta
9326insA c.9098_9099insA (p.Gln3034fs) Duplication 9 (1.85%) 2 (22.22%) - 0.00074 Palermo and Agrigento
L2865X c.8594T > A (p.Leu2865Ter) SNV 8 (1.66%) 3 (37.5%) - 0.00111 Palermo
V211I c.631G > A (p.Val211Ile) SNV 8 (1.66%) 4 (50.0%) - 0.00148 Agrigento, Siracusa andRagusa
6714del4 c.6482_6485ACAA [1](p.Lys2162fs) Deletion 6 (1.24%) 1 (16.66%)
ExAC
0.000017
GnomAD
0.000009
0.00037 Messina
9254del5 (Y3009fs) c.9026_9030del (p.Tyr3009fs) Deletion 6 (1.24%) 3 (50.0%) GnomAD0.000004 0.00111 Palermo
6265A > T (K2013X) c.6037A > T (p.Lys2013Ter) SNV 5 (1.03%) 1 (20.0%) GnomAD0.000004 0.00037 Erice
Q2561X c.7681C > T (p.Gln2561Ter) SNV 5 (1.03%) 1 (20.0%) - 0.00037 Palermo and Messina
3036del4 (A938fs) c.2808_2811del (p.Ala938Profs) Deletion 5 (1.03%) 2 (40.0%)
ExAC
0.000017
GnomAD
0.000008
0.00074 Caltanissetta
4512insT c.4284dup (p.Gln1429fs) Duplication 4 (0.82%) 3 (75.0%) GnomAD0.000004 0.00111 Palermo
2070insT c.1842dupT (p.Asn615Terfs) Duplication 4 (0.82%) 1 (25.0%) - 0.00037 Agrigento
IVS21 + 4A > G c.8754 + 4A > G SNV 4 (0.82%) 2 (50.0%) - 0.00074 Catania
* Dataset ExAC v1.0; ** Datase GnomAD v2.1.1.
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Furthermore, another PV named BRCA2-6079del4 (HGVS nomenclature: c.5851_5854del;
p.Ser1951fs) [50–52] was also detected in some families from North-western Sicily (17 individuals,
including 8 cancer patients) belonging to the geographical area that includes the cities of Palermo and
Trapani and neighboring areas. Among cancer patients harboring this PV, 5 individuals had female
breast cancer, 2 male breast cancer and one both primary ovarian and breast cancer. Another PV named
BRCA2-K2013X (HGVS nomenclature: c.6037A > T; p.Lys2013Ter) was exclusively detected in two
Sicilian families (five PV carriers) from the city of Erice (North-western Sicily).
Other PVs observed with lower recurrence in Sicilian families belonging to the geographical area
that includes the city of Palermo and neighboring areas are the following: BRCA1-1479delAG (HGVS
nomenclature: c.1356_1357AG [2]; p.Glu453_Ser454insTer), BRCA1-R1443X (HGVS nomenclature:
c.4327C > T; p.Arg1443Ter), BRCA1-5149del4 (HGVS nomenclature: c.5030_5033del; p.Thr1677fs),
BRCA1-3347delAG (HGVS nomenclature: c.3226_3227AG [1]; p.Gly1077fs), BRCA1-916delTT (HGVS
nomenclature: c.798_799del; p.Ser267fs). Interestingly, BRCA1-R1443X has been reported as a founder
variant in the French Canadian population [53], BRCA1-3347delAG as a founder mutation both in Italy
(Tuscany) and Norway [38], BRCA1-916delTT as a North African founder variant [54].
The three most represented PVs, observed in families from the Sicilian hinterland, especially
in those belonging to the geographical area that includes the city of Caltanissetta and neighboring
areas (for example, the small town of Mussomeli), are named BRCA1-5149del4 (HGVS nomenclature:
c.5030_5033del; p.Thr1677fs), BRCA1-E1302X (HGVS nomenclature: c.3904G > T; p.Glu1302Ter),
BRCA2-3036del4 (HGVS nomenclature: c.2808_2811del; p.Ala938Profs). Interestingly, BRCA2-3036del4
has been described as a founder variant in Western Europeans [55].
Furthermore, a common Ashkenazi founder PV consisting of a BRCA1 duplication named 5382insC
(HGVS nomenclature: c.5266dupC; p.Gln1756Profs) [56] has been mainly observed in some families
from the North-eastern coast of Sicily belonging to the city of Messina (11 individuals, including 6
cancer patients). Among cancer patients harboring this PV, 5 subjects had breast cancer (3 of which
TNBC) and 1 had ovarian cancer. Interestingly, this variant was reported as a founder mutation also
in several European populations (Austrian, Slovenian, German, Czech, Hungarian, Greek, Danish,
Polish, Latvian, Lithuanian, Belarusian and Russian) [53].
In addition, another common Ashkenazi founder PV named BRCA1-185delAG was detected in
one Sicilian family (3 individuals, one of which with BC) from the city of Ragusa (Table S1).
Another recurrent founder PV, named BRCA1-C61G (HGVS nomenclature: c.181T > G; p.Cys61Gly)
and identified mainly in Eastern European populations (Polish, Czech, Slovenian, Austrian, Hungarian,
Belarusian and German) [38], has also been observed in our study population (8 PV carriers, including
2 cancer patients). Also the BRCA2-9326insA founder variant, usually present in Germany and
Hungary [38], was detected in Sicilian individuals (7 PV carriers, 2 of which cancer patients) from the
cities of Palermo and Agrigento. Conversely, the BRCA2-9254del5 founder mutation originating in the
Northeast Spanish [57] was observed in 6 Sicilian subjects, including 3 cancer patients, from the city of
Palermo. Finally, two PVs named BRCA1-3372insA (HGVS nomenclature: c.3253dupA; p.Arg1085Lysfs)
and BRCA2-IVS21 + 4A > G (HGVS nomenclature: c.8754 + 4A > G) have been detected in some
families belonging to the geographical area that includes the city of Catania and neighboring areas.
The distribution of the most frequent BRCA1/2 PVs in different geographical areas of Sicily is
shown in Figure 3.
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3. Discussion
In the last years, thanks to advances in genetic sequencing techniques, the field of genetic testing
for breast and ovarian cancers has deeply evolved. Our improved ability of profiling the molecular
and genetic features of tumors has allowed for a better and more accurate detection of ger line but
also somatic, PVs in several genes, including BRCA1/2, resulting in a deeper understanding of the
cancer risk related to heredo-familial tumor syndromes. Germline BRCA PVs occur in 10–20% of
TNBC patients and are especially common among BC patients with BRCA1 PV than BRCA2 PV carriers
or non-carriers.
In our work, we have retrospectively collected and analyzed all clinical information of 1346 HBOC
patients enrolled from January 1999 to October 2019 at our Centre and genetically tested for germline
PVs in BRCA1 and BRCA2 genes. Our study has mainly focused on both the epidemiological impact
of the germline BRC PVs found in the Sicilian population and geographical distribution of these
variants. The comparison between all genetically tested individuals (probands and family members)
harboring PVs in BRCA1 and BRCA2 genes showed that there is no a clear prevalence of variants in
one gene rather than the other in the Sicilian population, confirming the epidemiological and genetic
data previously reported in literature. Specifically, 53% of analyzed BRCA-positive subjects carried a
BRCA1 PV, 46% harbored a BRCA2 PV and 1% was characterized by simultaneous presence of PVs
in BRCA1 and BRCA2 genes. As regards the typology of cancer associated with HBOC syndrome
in the BRCA1 PV carriers, 60% of tumors was represented by female BC, 26% by OC, 10% by both
(primary BC and OC) and finally 3% by male BC. Instead, BRCA2 PV carriers showed female BC in
74% of cases, OC in 16%, primary BC and OC in 5% and male BC in remaining 5%. By comparing
the previous data, we have observed that BRCA1 PV carrier patients show a higher frequency of OC
(26% vs. 16%) and synchronous or metachronous primary BC and OC, compared to BRCA2 PV carrier
patients. Conversely, BRCA2 PV carrier patients have been observed to exhibit a higher incidence of
female BC (74% vs. 60%) characterized by earlier age of onset (diagnosis under age 35 years: 26% vs.
11%), bilateral female BC and male BC, compared to BRCA1 PV carrier patients. Furthermore, it has
been observed that the mean and median ages of onset for BC were similar for PV carriers in both
genes. Instead, BRCA2 PV carrier patients showed, not only a lower frequency of OC but also a later
onset age of disease (mean age at diagnosis: 60.6y vs. 52y; median age at diagnosis: 57y vs. 51y),
compared to the BRCA1 PV carrier patients.
Subsequently, we investigated the prevalence and geographic distribution of inherited PVs in
BRCA1/2 genes in the Sicilian population.
Several studies have reported numerous differences and a significant heterogeneity in the
prevalence of PVs across different populations [34,58]. Based on these data, the cancer risk estimates
could also be modified by race and ethnic origin. “Founder” mutations, originated from an ancestor
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population and maintained over time, were observed in specific geographic areas [59]. Significant
evidence from founder mutation testing carried out mainly on the Jewish population allowed to
develop new population-based genetic approaches that, in the future, could help to increase the BRCA
carrier detection rates and maximize prevention strategies [34].
DNA sequence variants with “founder effect” were observed, for the first time, in Ashkenazi Jews,
who have been shown to harbor a BRCA1 PV named 185delAG in 1% of cases, resulting in a 16–20%
BC risk below the age of 50 years [60]. Afterwards, other founder mutations have also been identified
in various European populations [38,61]. Two PVs named BRCA1-5083del19 and BRCA2-8765delAG
have shown a significant prevalence in Italian population [62,63]. The BRCA1-5083del19 PV was
identified as founder mutation in families of Calabrian origin and, more recently, in numerous families
of Sicilian origin [41]. Instead, BRCA2-8765delAG, detected in families with multiple cases of HBOC,
was reported as a founder PV for several populations, including Northern Sardinian, French Canadians,
Jewish-Yemenites and Czechs [62]. Several evidence supports the hypothesis that the 8765delAG
variant occurred at least twice in different populations, since its position in an AG-rich sequence
may represent a mutational hot-spot [62]. Finally, the PV named BRCA1-1499insA is considered a
hypothetical founder variant in Tuscany [64].
Ninety-nine germline BRCA1/2 variants, 58 of which in BRCA2 and 41 in BRCA1, have been
identified in the Sicilian families genetically tested in our study by mutational screening. We have
observed that 30 PVs were more frequently detected in the examined Sicilian population but only
some of these appeared more interesting in terms of territorial prevalence. As already previously
reported [41], the BRCA1-5083del19 founder variant is resulted to be the most widespread PV in the
Sicilian population, since it has been detected in 18 Sicilian families for a total of 63 carriers. This variant
appears to be mainly widespread in the Western Sicily, in particular in the geographical areas that
include Palermo and nearby cities (Bagheria, Roccamena, etc.) and Agrigento and neighboring towns
(Sambuca, Sciacca, Santa Margherita di Belice). However, a haplotype analysis is required in all
BRCA1-positive carriers present in Italy, in order to explain whether the Calabrian and Sicilian families
have a common ancestor.
Conversely, the other potential Sicilian founder variant named BRCA1-4843delC seems to be
poorly represented in the Sicilian population, because it has been detected only in 7 individuals from
the city of Palermo.
Also other two PVs named BRCA2-1466delT and BRCA1-633delC are resulted to be prevalent in
the Sicilian population, because they have been observed in 12 (49 carriers) and 14 (38 carriers) families,
respectively. Interestingly, since these two PVs have been rarely observed in other Italian regions or in
the world, therefore they could be worthy of a more in-depth study in order to establish whether or
not they are variants specific for the Sicilian population.
Almost all patients who harbored the BRCA2-1466delT variant showed a higher genetic
predisposition to developing BC. This is a PV mainly detected in several families from the North-Western
Sicily, especially in the geographical area that includes the city of Palermo and nearby areas.
Interestingly, this variant seems to be very frequent mostly in Sicilian families from the small town of
Montemaggiore Belsito.
The BRCA1-633delC variant was mainly observed in some families from the Tyrrhenian side
of Sicily, especially in the geographical areas that include the cities of Palermo (western coast) and
Messina (eastern coast) and respective neighboring areas.
Furthermore, other PVs, such as BRCA2-6310del5, BRCA1-E1302X, BRCA1-3372insA,
BRCA2-K2013X and BRCA2-2070insT, deserve a more in-depth study not so much for a significant
numerical incidence as for a specific territorial prevalence and segregation. Indeed, also these PVs
have not been frequently detected in other countries or regions.
The BRCA2-6310del5 PV has been mainly detected in some families belonging to the geographical
area that includes the city of Trapani (North-Western Sicily), whereas the BRCA2-K2013X variant has
been exclusively observed in some individuals from the city of Erice, a small town near Trapani.
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The BRCA1-E1302X PV is resulted to be prevalent in a few families from the Sicilian hinterland,
especially in the geographical area to which Caltanissetta belongs together with the nearby small
town of Mussomeli. BRCA1-3372insA and BRCA2-2070insT, instead, seem to be PVs exclusive of the
geographical areas that include the city of Catania (particularly, the smalls towns of Fiumefreddo
di Sicilia and Aci Sant’Antonio) and Agrigento (especially, the small town of Raffadali), respectively.
Finally, the BRCA2-V211I PV did not show territorial prevalence, but, in all cases examined in this
study, is resulted to be associated with the emergence of bilateral female BC.
In conclusion, our study showed that, unlike other Italian and European regions, some PVs
observed in the Sicilian population have been shown to be more recurrent. This difference could be
attributed to several factors including, for example, the historical background of the Sicily and its
crucial geographical location in the center of the Mediterranean Sea, crossroads of several cultures and
civilizations. In fact, the different peoples, such as Greeks, Romans, Arabs, Normans, Phoenicians,
Etruscans, Byzantines, who dominated this region throughout history are probably responsible for
the genetic heterogeneity of the Sicilian families, already reported for allelic variants of hemoglobin
in Beta Thalassemia [65]. A further proof of this genetic heterogeneity reflecting the coexistence of
different past cultures in Sicily may be provided by the presence in some Sicilian families of some
specific founder variants observed in other countries (mostly Europe). In this context, for example,
interestingly, two common Ashkenazi founder PVs, named BRCA1-5382insC and BRCA1-185delAG,
were also observed in our study population, albeit with different frequencies.
The development of new population-based genetic approaches may help to detect the 50% more
BRCA-carriers than those identified by classical clinical and familial criteria, as already shown in other
studies [34].
Additionally, a more in-depth understanding of the correlations between described BRCA PVs
and clinical features of HBOC syndrome patients could be the key to develop tailored treatment for
BRCA-related cancer patients and better strategies for prevention and surveillance of BRCA-positive
carriers without disease. Finally, several studies showed the association between specific BRCA1/2
PVs and variations of breast and ovarian cancer relative risks [66]. Further investigations on this
issue could help to better understanding the pression of genotype on tumor phenotype, favoring the
development of tailored strategies for prevention, surveillance and treatment.
4. Materials and Methods
4.1. Study Population
This is a retrospective study based on BRCA1/2 genetic testing results and clinical record review.
We reviewed genetic, clinical and demographic data of patients with breast and/or ovarian cancer
who underwent BRCA1/2 genetic testing from January 1999 to October 2019 at the “Sicilian Regional
Center for the Prevention, Diagnosis and Treatment of Rare and Heredo-Familial Tumors” of the
Section of Medical Oncology of University Hospital Policlinico “P. Giaccone” of Palermo. Genetic
counselling was performed by a multidisciplinary team, consisting mainly of an oncologist, a geneticist
and a psychologist, who has collected all information regarding the personal and familial history
of patients. For each family, the youngest member with breast and/or ovarian cancer has been
selected as index case for the mutational screening. The information about cancer diagnosis and
histological subtype was retrieved by pathology reports. Following the genetic counselling for
evaluation of risk of HBOC syndrome, the patients were selected for germline BRCA1/2 testing based
on probability rate of carrying PV assessed by BRCAPRO genetic risk prediction model [67] and
according to the previously established criteria by the Italian Association of Medical Oncology (AIOM).
(https://www.aiom.it/linee-guida-aiom-2018-neoplasie-della-mammella-11/). These criteria are based
on personal and family history and age of cancer onset, in order to identify individuals at high risk of
harboring a PV in the HBOC predisposition genes. The following criteria were used to select patients to
be genetically tested for germline BRCA1/2 PVs: (i) Personal history of (a) male with BC; (b) women with
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breast and ovarian cancer; (c) woman with BC <36 years; (d) woman with TNBC <60 years (starting
from year 2017); (e) woman with bilateral BC <50 years; (ii) Personal history of BC <50 years and at
least 1 first-degree relative with: (a) BC <50 years; (b) non-mucinous and non-borderline OC at any age;
(c) bilateral BC; (d) male BC; (iii) Personal history of BC >50 years and family history of breast or ovarian
cancer in two or more relatives who have a first degree relationship with each other (including 1 who
has a first-degree relationship with her); (iv) Family history of known PV in a predisposing gene [27].
The Italian Association of Medical Oncology (AIOM) every year updates its guidelines for identifying
the individuals who should receive BRCA genetic testing, and, in the last version published at October
2019, AIOM expanded the population to be genetically tested, including the patients with advanced
pancreatic cancer (https://www.aiom.it/wp-content/uploads/2019/10/2019_Racc_BRCA_pancreas.pdf).
All the most relevant genetic, clinical and demographic information, including age of cancer
diagnosis, histological subtype, personal and familial history and family geographical origin,
was anonymously recorded and coded for all tested patients who previously provided written
informed consent.
The BRCA test result was considered informative, when a pathogenic or likely pathogenic variant
was identified in an individual. Conversely, BRCA test result was considered not informative, when no
pathogenic or likely pathogenic variant was identified but its presence could not be excluded or a VUS
to which it was not possible to attribute a risk value was detected.
Patients harboring a germline PV in BRCA1/2 genes were addressed to enhanced screening
programs and/or risk-reducing surgical strategies by a professional with expertise in cancer genetics.
Targeted BRCA1/2 testing was proposed and extended to the first-degree family members of
BRCA-variant patients, after providing informed consent.
Geographical origin of the examined Sicilian families was assessed based on the place of birth of
index cases and tested family members. Afterwards, individuals harboring a BRCA1/2 PV were divided
into different geographical groups based on their original place of birth, considering the main cities of
Sicily (Palermo, Catania, Messina, Agrigento, Caltanissetta, Trapani, etc.) and respective neighboring
areas. Subjects from neighboring small towns have been included in the same geographical area of
respective main city.
4.2. Sample Collection and Next-Generation Sequencing Analysis for BRCA 1/2 Genes
Peripheral blood samples were collected from HBOC patients. Genomic DNA was isolated
from the peripheral blood using the DNeasy® Blood Kit (QIAGEN, Hilden, Germany), quantified by
Qubit®3.0 fluorometer (Thermofisher Scientific, Waltham, MA, USA) and its quality was assessed by
using 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). We used 4 ng of DNA to prepare the
barcoded library using BRCA Screen kit (4bases SA) that has allowed to investigate all the exons of
BRCA1 (NM_007300.3) and BRCA2 (NM_000059.3) genes. The kit consists of three multiplex PCR
primer pools. We used 20 nanograms of DNA per primer pool for multiplex PCR amplification,
followed by ligation of a barcode and purification with Agentcourt AMPureXP reagent (Beckman
Coulter, Beverly, MA, USA). The quantity and the quality of prepared libraries were evaluated using
Qubit®3.0 fluorometer (Thermofisher Scientific) and Agilent 2100 Bioanalyzer on-chip electrophoresis
(Agilent Technologies), respectively, as previously described [68]. Subsequently, libraries were mixed in
an equimolar ratio and emulsion PCR was performed with the Ion OneTouch OT2 System (Thermofisher
Scientific) using Ion 520 & Ion 530 Kit-OT2 (Thermofisher Scientific). Finally, sequencing was performed
with Ion 520 Chip (Thermofisher Scientific) using Ion Torrent S5 (Thermofisher Scientific) instrument.
The sequencing data was analyzed with Amplicon Suite (SmartSeq s.r.l.) and Ion Reporter Software
v.5.12 (Thermofisher Scientific).
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4.3. Sanger Sequencing
Pathogenic, likely pathogenic and VUS variants of BRCA1/2 genes were confirmed by Sanger
sequencing using a BigDye Therminator 3.1 Cycle Sequencing Kit (Life Technologies) and read through
the 3130xl Genetic Analyzer (Applied Biosystems), according to the manufacturer’s protocols.
4.4. CNV Analysis by Multiplex Ligation-Dependent Probe Amplification Analysis (MLPA)
The presence of Large Genomic Rearrangements (LGR) was additionally tested by Multiplex
ligation-dependent probe amplification (MLPA), using the SALSA MLPA probemix P002-C2 for BRCA1
gene and SALSA MLPA Probemix P090 for BRCA2 gene according to the manufacturer’s instructions
(MRC–Holland, Amsterdam, the Netherlands). Probe amplification products were analyzed by
capillary electrophoresis using ABI 3130 Genetic Analyzer (Applied Biosystems). Results were
analyzed by GeneMapper™ Software Version 3.5 (Applied Biosystems) to determine peak heights
and areas and fragment sizes in base pairs (bp), as described previously [69]. Positive results were
confirmed with an additional analysis using the same kit on a second blood sample.
4.5. Genetic Variant Classification
The BRCA genetic variants were screened based on the classification criteria developed by the
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) consortium
(https://enigmaconsortium.org/) and according to IARC recommendations [35], using a system of
division into five classes—benign (class I), likely benign (class II), variant of uncertain significance
(VUS, class III), likely pathogenic (class IV) and pathogenic (class V). Several databases, such as ClinVar,
BRCA Exchange, LOVD, were used for the search and classification of BRCA variants.
The BRCA PVs identified in BRCA-positive carriers were named according to the systematic
nomenclature of The Breast Cancer Information Core (BIC) database (http://research.nhgri.nih.gov/
bic/) [70] and to the recommendations for the description of sequence variants established by the
Human Genome Variation Society (HGVS). HGVS nomenclature was authorized by the HGVS, Human
Variome Project (HVP) and the Human Genome Organization (HUGO) [71].
5. Conclusions
Since the Sicilian population is genetically different from the peoples of Europe and Northern
Italy, probably due to its historical background, hereditary breast and ovarian cancers could be
predominantly caused by BRCA1/2 PVs less recurrent than those usually detected in other geographical
areas of Italy and Europe.
Our investigation has led us to hypothesize that a higher prevalence of some germline BRCA PVs
in Sicilian families could be a population-specific genetic feature of BRCA-positive carriers.
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